An undifferentiated stem cell-removing agent which contains at least one kind selected from the group consisting of a fatty acid synthesis inhibitor, a fatty acid utilization inhibitor, and a cholesterol synthesis inhibitor; a method for removing undifferentiated stem cells which includes culturing a cell mixture that contains an undifferentiated stem cell and a differentiated cell in the presence of the undifferentiated stem cell-removing agent; and a production method of cells for transplantation which includes the following steps (i) and (ii): a step (i) of inducing a desired differentiated cell from an undifferentiated stem cell, and a step (ii) of culturing the cell mixture obtained in the step (i) in the presence of the undifferentiated stem cell-removing agent are provided.

The present disclosure provides methods of reducing protein misfolding and/or aggregation in a cell. The present disclosure provides methods of treating diseases and disorders associated with protein misfolding and/or aggregation.

Disclosed are long non-coding RNAs (IncRNAS) for TROLL-8. It is shown herein that IncRNAs TROLL-8, is a suitable target for cancer therapies and can be used to make prognostic determinations about a cancer. Specifically, the disclosure provides a method of assessing tumor grade and/or progression of a cancer and/or metastasis in a subject comprising obtaining a tissue sample from a subject and measuring the expression level of the long non-coding RNA for TROLL-8; wherein the higher the level of IncRNA for TROLL-8, the greater the severity and/or invasiveness of the tumor is indicated. Further disclosed is a method of assessing the efficacy of a cancer treatment regimen administered to a subject, the method comprising measuring the expression level of the long non-coding RNA for TROLL-8 in a tissue sample from the subject relative to a control.